Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dental amalgam call-for-papers

This article was originally published in The Gray Sheet

Executive Summary

FDA seeks reference information for peer-reviewed journal articles that discuss the health impact of dental amalgam and were published from Jan. 1, 1996 to June 1, 2003. Submissions to FDA are due by June 2. The 1May 9 request is part of FDA's preparation for the latest in a series of literature reviews on the topic that will start later this year. Sponsored by FDA, CDC and the National Institute of Dental & Craniofacial Research, the review will be conducted by an independent group. Prior reviews concluded that, for the most part, dental amalgam poses no serious health threat. Last month, however, Rep. Diane Watson (R-Calif.) introduced 2HR 1680, a bill seeking to ban use of mercury fillings introduced into interstate commerce after 2008...

You may also be interested in...



Dental amalgams

Stakeholders are granted an additional month to send FDA peer-reviewed articles dealing with dental amalgam health risks. Submissions are now due by July 1 (1"The Gray Sheet" May 12, 2003, In Brief)...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel